Cancer, Multiple Myeloma


Article Author:
Sara Albagoush


Article Editor:
Alexandre Azevedo


Editors In Chief:
Temekis Hampton


Managing Editors:
Orawan Chaigasame
Carrie Smith
Abdul Waheed
Frank Smeeks
Kristina Soman-Faulkner
Benjamin Eovaldi
Radia Jamil
Sobhan Daneshfar
Saad Nazir
William Gossman
Pritesh Sheth
Hassam Zulfiqar
Navid Mahabadi
Steve Bhimji
John Shell
Matthew Varacallo
Ahmad Malik
Mark Pellegrini
James Hughes
Beata Beatty
Hajira Basit
Phillip Hynes


Updated:
3/19/2019 7:03:04 PM

Introduction

Multiple myeloma (MM) is a clonal plasma cell proliferative disorder characterized by the abnormal increase of monoclonal paraprotein leading to evidence of specific end-organ damage. MM is part of the spectrum of monoclonal gammopathy. Monoclonal gammopathy of undetermined significance (MGUS), in other words, detection of monoclonal immunoglobulin in blood or urine without evidence of end-organ damage, has a progression risk to MM of about 1% per year. Smoldering multiple myeloma (SMM), the next stage in the spectrum of monoclonal gammopathy, is at a much higher progression risk of 10% per year.

Etiology

The exact etiology of MM is unknown. However, there is evidence that suggests genetic abnormalities in oncogenes such as CMYC, NRAS, and KRAS may play a role in the development of plasma cell proliferation. MM has also been associated with other factors such as drinking alcohol, obesity, environmental causes such as insecticides, organic solvents), and radiation exposure.[1]

Epidemiology

MM represents 1.8% of all new cancer cases in the United States. It occurs predominantly in the geriatric population with a median age at diagnosis of about 70 years. The number of cases diagnosed annually is expected almost to double in 20 years. It has a male-to-female ratio of 3 to 2 and is more common among African-Americans.[2]

Pathophysiology

MM is thought to arise from a pre-malignant, asymptomatic stage of clonal plasma cell growth called monoclonal gammopathy of undetermined significance (MGUS), which is known to be detectable in over 3 percent of persons above age 50. It appears that the cell of origin is a post-germinal center plasma cell. Clinical progression to overt MM occurs at a rate of approximately 1% per year.[3]

Although the exact causes of MGUS development and progression to MM remain unknown, the 2 fundamental steps in MM pathogenesis are:

  • Establishment of MGUS: Possibly because of cytogenetic abnormalities generated during an abnormal response to antigenic challenge, which results in monoclonal immunoglobulin production;
  • Progression from MGUS to MM: Under the "second hit" hypothesis, progression is thought to be a consequence of additional cytogenetic lesions gained by the original plasma cell clone, caused either by genetic instability or abnormalities in the hematopoietic microenvironment.

Malignant plasma cells in MM are especially sensitive to interleukin-6, which appears to be essential for tumor growth and survival.

Excess monoclonal immunoglobulin can cause hyperviscosity, platelet dysfunction and renal tubular damage, leading respectively to neurologic derangement, bleeding, and renal failure. Bone marrow occupation by the expanding plasma cell clone usually manifests as anemia, thrombocytopenia, and leukopenia.

The interaction between myeloma cells and the bone microenvironment ultimately leads to the activation of osteoclasts and suppression of osteoblasts, resulting in bone loss. Several intracellular and intercellular signaling cascades, numerous chemokines and interleukins are implicated in this complex process.

Histopathology

A bone marrow aspirate and biopsy are usually performed to estimate the percentage of abnormal plasma cells. This percentage is required in the diagnostic criteria for myeloma.

The plasma cells seen in MM have several possible morphologies. First, they could take the form of a mature, normal plasma cell (a large cell, 2 or 3-times the size of a lymphocyte, with a single eccentric nucleus displaced by an abundant, basophilic cytoplasm). The Golgi apparatus will typically produce a light-colored area next to the nucleus, called a perinuclear halo. Second, they can have features of immaturity, such as low nuclear-cytoplasmic ratio, larger size, loose chromatin (i.e., a plasmablast). Other possible morphologies are bizarre, multinucleated cells, "flame cells" with fiery red cytoplasm, or Mott cells that show multiple clustered cytoplasmic droplets. Bone marrow is usually hypercellular and diffusely infiltrated by plasma cells. Rarely, plasma cells can be seen in peripheral blood (plasma cell leukemia).

Immunohistochemistry can detect plasma cells which express immunoglobulin in the cytoplasm and occasionally on the cell surface; myeloma cells are typically CD56, CD38, CD 138, CD319-positive, and CD19 and CD45-negative. Clonality is confirmed by kappa or lambda light chain restriction.

History and Physical

The presentation can vary from asymptomatic to severely ill. Usually, the patient is an older adult complaining of constitutional symptoms such as fatigue, weight loss, and bone pain, particularly in the back and chest. Pathological fractures and vertebral collapse lead to a reduction in height, spinal cord compression, radicular pain or kyphosis. Anemia usually causes pallor, palpitation and worsening of previous heart failure or angina. Renal failure (acute and/or chronic) can lead to edema, acidosis, and electrolyte disturbances. Hypercalcemia, dehydration, and hypergammaglobulinemia further aggravate renal injury and may lead to confusion, obtundation, and coma. Secondary amyloidosis can cause peripheral neuropathy and carpal tunnel syndrome, which manifest as paresthesias and muscle weakness. A few patients may present with hepatomegaly, splenomegaly, lymphadenopathy, and fever.

Those with hyperviscosity may have symptoms like paresthesia, headache, dyspnea, nasal bleeding, blurry vision. Lung involvement in the form of pleural effusion or diffuse pulmonary infiltration by plasma cells is a rare presentation.

MM patients are more prone to infections, mostly pneumonia, and pyelonephritis. Findings on physical examination are variable depending on the extent of disease, but will usually include pallor, tachycardia, tachypnea, petechiae or ecchymoses, bone tenderness, edema or signs of dehydration and central or peripheral neurologic signs. Fundoscopic signs include exudative macular detachment, retinal hemorrhage or cotton-wool spots. Carpal tunnel syndrome may cause positive Tinel and Phalen signs. Extra-medullary plasmacytomas can present as deep-seated or superficial tumors. Macroglossia, papules, or nodules can occur in amyloidosis.

Evaluation

According to the National Comprehensive Cancer Network (NCCN) criteria, MM is defined as smoldering (asymptomatic) or active (symptomatic).[4]

NCCN criteria for smoldering MM:

  • Serum monoclonal protein: IgG or IgA equal to 3 g/dL or
  • Bence Jones protein equal to 500 mg per 24 hours and/or
  • Clonal bone marrow plasma cells 10% to 59%  and
  • The absence of myeloma-defining events or amyloidosis

The NCCN also recommends that a patient whose bone survey is negative be assessed for bone disease with whole-body or skeletal MRI, with contrast, or whole-body PET/CT to differentiate active from smoldering MM.

Per NCCN guidelines, an active multiple myeloma is no longer diagnosed using the CRAB criteria (hypercalcemia, renal failure, anemia, bone lesions) for end-organ damage. The current diagnostic criteria are: 

  • Bone marrow clonal plasma cells equal to 10% or bony or extramedullary plasmacytoma (confirmed by biopsy) and
  • One or more myeloma-defining events, including: 
  • Serum calcium level greater than 0.25 mmol/L (greater than 1 mg/dL) higher than the upper limit of normal or greater than 2.75 mmol/L (greater than 11 mg/dL)
  • Renal insufficiency (creatinine greater than 2 mg/dL [greater than 177 micromol/L] or creatinine clearance less than 40 mL per minute)
  • Anemia (hemoglobin less than 10 g/dL or hemoglobin greater than 2 g/dL below the lower limit of normal)
  • One or more osteolytic bone lesions on skeletal radiography, CT, or PET-CT

 In November 2014, the International Myeloma Working Group (IMWG) added the following criteria to the CRAB criteria for MM:

  • Bone marrow plasma cells (BMPCs) equal to 60%
  • Involved/uninvolved serum free light chain ratio equal to 100
  • Abnormal MRI with more than one focal lesion, with each lesion greater than 5 mm

The IMWG noted that these findings have been "associated with near inevitable development of CRAB features in patients who would otherwise be regarded as having smoldering multiple myeloma." The presence of any CRAB criterium or any of these three additional criteria justifies therapy.

Suspected MM workup is targeted to check if the patient meets diagnostic criteria and, if so, what is the stage. Depending on the stage, the most appropriate management strategy is chosen.

The NCCN guidelines recommend the following diagnostic studies:

  • Complete blood count (CBC) with differential, platelet count
  • BUN, creatinine, electrolytes, albumin, calcium levels
  • Serum LDH and beta-2 microglobulin
  • Serum immunoglobulins, serum protein electrophoresis (SPEP), serum immunofixation electrophoresis (SIFE)
  • 24-hour proteinuria, urine protein electrophoresis (UPEP), urine immunofixation electrophoresis (UIFE)
  • Serum free light chain (FLC) assay
  • Skeletal survey
  • Unilateral bone marrow aspirate and biopsy, including immunohistochemistry and/or flow cytometry, and cytogenetics
  • Plasma cell FISH [del 13, del 17p13, t(4;14), t(11;14), t(14;16), 1q21 amplification], 1p abnormality

In patients with severe hypergammaglobulinemia, "rouleaux" formation of RBCs can be evident at hematoscopy.

A skeletal survey usually shows lytic lesions of any bone. The classic image on skull x-ray studies is the punched-out, round, radiolucent lesion ("pepper pot skull"). Less often, lesions may take a sclerotic appearance. MRI is more sensitive than plain X-rays in the detection of lytic lesions. Occasionally, CT scan is performed to measure the size of soft tissue plasmacytomas.

Treatment / Management

Initial therapy of MM varies depending on disease risk stratification and functional status, which will help determine transplant eligibility. Patients who are fit for transplant typically receive induction therapy for a few months to decrease the tumor burden, followed by peripheral blood stem cell mobilization and harvesting, and finally, an autologous transplant. For transplant-ineligible patients, common regimens include lenalidomide and dexamethasone, bortezomib and dexamethasone, melphalan/prednisone/bortezomib, and other bortezomib-based regimens. Novel agents such as oral proteasome inhibitors (e.g., ixazomib) and monoclonal antibodies (e.g., daratumumab) have shown promising results.

For symptomatic anemia, blood transfusion and sometimes erythropoiesis-stimulating agents are used.

Plasmapheresis is used for the hyperviscosity syndrome.

Hypercalcemia and renal failure treatments include hydration, glucocorticoids, bisphosphonates, calcitonin, and hemodialysis. Patients with MM should take measures to reduce renal damage by avoiding nephrotoxic agents (e.g., NSAIDs, contrast agents, diuretics, aminoglycosides) and maintaining good hydration. Many medications used for MM treatment may require dose adjustment in order to reduce kidney damage.

MM patients are more prone to infections. Prophylactic measures include yearly influenza vaccine, pneumococcal vaccine at the time of diagnosis, prophylactic antibiotics and hematopoietic growth factors during the first few months of chemotherapy induction, intravenous immunoglobulin for patients with recurrent infections.

Bone pain usually requires opioids for control.

Spinal cord compression by vertebral fracture or plasmacytoma is a medical emergency and should be managed aggressively with radiotherapy and orthopedic consultation.

Differential Diagnosis

Waldenstrom's macroglobulinemia: Type of M protein is IgM, and the clinical features differ from those in MM.

Monoclonal Gammopathy of Undetermined Significance (MGUS) 

  • No end-organ damage
  • Serum monoclonal protein less than 3 g/dl
  • Clonal bone marrow plasma cells less than 10%

Smoldering Multiple Myeloma

  • No end-organ damage
  • Monoclonal protein equal to or over 3 g/dl
  • Clonal bone marrow plasma cells 10% to 59%

Medical Oncology

Initial Therapy[5] 

The preferred treatment for those under the age of 65 is chemotherapy, commonly with bortezomib-based regimens, and lenalidomide-dexamethasone, followed by high-dose therapy with melphalan and autologous hematopoietic stem-cell transplantation (ASCT). Autologous transplantation prolongs overall survival and complete remission, but is not considered curative. Allogenic stem cell transplantation can be theoretically curative but is not used as frontline therapy owing to its high treatment-related mortality in older patients, who make up most MM cases. 

People older than age 65 and those with a significant concurrent illness often cannot tolerate stem cell transplantation. The standard of care has been chemotherapy with combinations of melphalan, bortezomib, and lenalidomide plus low-dose dexamethasone or prednisone. Newer agents like carfilzomib and elotuzumab are also being used recently.

Relapse

Several newer options have been recently approved for the management of advanced disease: 

  • Ixazomib, an orally available proteasome inhibitor, in combination with lenalidomide and dexamethasone
  • Panobinostat, an orally available histone deacetylase inhibitor, in combination with bortezomib and dexamethasone
  • Carfilzomib, a newer generation proteasome inhibitor used for the treatment of relapsed or refractory disease, either as a single agent or in combination with dexamethasone and/or lenalidomide 
  • Elotuzumab, an immunostimulatory humanized monoclonal antibody against SLAMF7 (CD139)
  • Daratumumab, a monoclonal antibody against CD38

Staging

Main Staging Systems

International Staging System (ISS)[6]

Incorporates data on the levels of serum-beta-2 microglobulin (B2M) and serum albumin to divide disease burden into three stages with prognostic significance:

  • Stage 1: B2M less than 3.5 mg/L and serum albumin greater than or equal to 3.5 g/dl
  • Stage 2: Neither stage 1 nor stage 3
  • Stage 3: B2M greater than or equal to 5.5 mg/L

Median overall survival for patients with ISS stages 1, 2, and 3 are 62, 44, and 29 months, respectively.

Revised International Staging System (R-ISS)[7]

Provides prognostic information that is more robust than that from the original ISS.

  • Stage 1: B2M less than 3.5 mg/L, albumin greater than or equal to 3.5 g/dL, normal LDH, and standard-risk cytogenetics
  • Stage 2: Neither stage 1 nor stage 3
  • Stage 3: B2M greater than 5.5 mg/L and high-risk cytogenetics* or elevated LDH

*del(17p), and/or t(4;14), and/or t(14,16)

Durie-Salmon Staging System[8]

For many years, before the introduction of the ISS, the Durie-Salmon staging system was the standard for risk stratification. It is based on the amount of hemoglobin and calcium in the blood, the presence of bone damage on x-rays and amount of monoclonal protein in the blood or urine. It divides patients into three stages (I, II, and III) and sub-classifies them further into groups A and B according to serum creatinine level.

Prognosis

Older patients will often have serious concomitant diseases, which affect survival. Younger patients have less treatment-related morbidity, and consequently, fare better.

In 2003, with high-dose therapy followed by autologous stem cell transplantation, median survival was estimated to be approximately 4.5 years, compared to a median of approximately 3.5 years with standard therapy. Overall, the 5-year survival rate is around 35%.[9]

Complications

Common manifestations and complications of multiple myeloma include hypercalcemia, renal insufficiency, infection, skeletal lesions, and anemia. Less common complications include venous thromboembolism and hyperviscosity syndrome. [10]

  • Renal insufficiency: Can be acute or chronic. A variety of etiologic mechanisms may be involved, including those related to the excess production of monoclonal light chains (light- chain cast nephropathy), deposition of intact light chains causing nephrotic syndrome, light chain amyloidosis, hypercalcemia, hyperuricemia, dehydration. Treatment is directed at the underlying cause.
  • Infection: Risk of infection is highest in the first 3 to 4 months of induction therapy, so prophylactic antibiotics are required for the first few months. Factors contributing to the increased risk of infection include impaired lymphocyte function, suppression of normal plasma cell function, hypogammaglobulinemia and chemotherapy-induced neutropenia. Most common infections are pneumonia and urinary tract infections, mostly with organisms such as Streptococcus pneumoniaHaemophilus influenzae, and Escherichia coli.
  • Skeletal lesions: Myeloma bone disease results from overexpression of RANKL by bone marrow stroma. RANKL activates osteoclasts, which resorb bone. Bone breakdown leads to the release of calcium into the blood, leading to hypercalcemia and symptoms of kidney failure that may develop acutely or chronically. It manifests as severe bone pain, pathological fractures, spinal cord compression.
  • Hypercalcemia: May be asymptomatic or cause anorexia, fatigue, constipation, polydipsia, polyuria, confusion or stupor. Treatment depends on clinical severity and rapidity of installation of hypercalcemia. It includes hydration, glucocorticoids, bisphosphonates, calcitonin and/or hemodialysis.
  • Hyperviscosity syndrome: Presents as oronasal bleeding, blurred vision, retinal hemorrhage, seizure, and other neurologic symptoms, confusion, dyspnea, and heart failure. Plasmapheresis promptly relieves symptoms.
  • Neuropathy: Related to the disease itself or side effects of treatment with drugs such as thalidomide, bortezomib or vincristine
  • Thrombosis: Immunomodulating agents such as thalidomide and lenalidomide are associated with increased thrombotic risk.

Postoperative and Rehabilitation Care

According to multiple national center treatment guidelines, early palliative care for people with advanced MM at the time of diagnosis is highly recommended. It helps to address the symptoms and eases the unwanted side effects.

Enhancing Healthcare Team Outcomes

Treatment of MM often requires an interprofessional approach:

  • Radiotherapy, neurosurgery and/or orthopedic consultation in patients with spinal cord compression
  • Nephrology consultation in cases of severe renal compromise requiring dialysis
  • Hematology-Oncology for bone marrow studies, plasmapheresis, transfusion support, chemo- and immunotherapy, stem cell harvesting and transplantation

Diagnosis is not always obvious, especially in older patients, given their increased comorbidities. MM should always be suspected in an elderly patient with normocytic anemia, bone pain and evidence of renal dysfunction. The overall survival in MM has improved over the last decade due to more accurate diagnosis and risk stratification, a better understanding of how toxicity and frailty can affect prognosis, the discovery of novel agents, and advances in supportive care during the post-transplant period. Although still considered an incurable disease, the present 5-year survival rate is 48.5%.


Interested in Participating?

We are looking for contributors to author, edit, and peer review our vast library of review articles and multiple choice questions. In as little as 2-3 hours you can make a significant contribution to your specialty. In return for a small amount of your time, you will receive free access to all content and you will be published as an author or editor in eBooks, apps, online CME/CE activities, and an online Learning Management System for students, teachers, and program directors that allows access to review materials in over 500 specialties.

Improve Content - Become an Author or Editor

This is an academic project designed to provide inexpensive peer-reviewed Apps, eBooks, and very soon an online CME/CE system to help students identify weaknesses and improve knowledge. We would like you to consider being an author or editor. Please click here to learn more. Thank you for you for your interest, the StatPearls Publishing Editorial Team.

Cancer, Multiple Myeloma - Questions

Take a quiz of the questions on this article.

Take Quiz
What is the most common primary bone tumor pathology in adults?



Click Your Answer Below


Would you like to access teaching points and more information on this topic?

Improve Content - Become an Author or Editor and get free access to the entire database, free eBooks, as well as free CME/CE as it becomes available. If interested, please click on "Sign Up" to register.

Purchase- Want immediate access to questions, answers, and teaching points? They can be purchased above at Apps and eBooks.


Sign Up
An elderly person presents with four rib lesions. Bence-Jones proteins are found in the urine. Which statement about this condition is false?



Click Your Answer Below


Would you like to access teaching points and more information on this topic?

Improve Content - Become an Author or Editor and get free access to the entire database, free eBooks, as well as free CME/CE as it becomes available. If interested, please click on "Sign Up" to register.

Purchase- Want immediate access to questions, answers, and teaching points? They can be purchased above at Apps and eBooks.


Sign Up
What composes Bence Jones proteins?



Click Your Answer Below


Would you like to access teaching points and more information on this topic?

Improve Content - Become an Author or Editor and get free access to the entire database, free eBooks, as well as free CME/CE as it becomes available. If interested, please click on "Sign Up" to register.

Purchase- Want immediate access to questions, answers, and teaching points? They can be purchased above at Apps and eBooks.


Sign Up
What is the most serious complication of multiple myeloma?



Click Your Answer Below


Would you like to access teaching points and more information on this topic?

Improve Content - Become an Author or Editor and get free access to the entire database, free eBooks, as well as free CME/CE as it becomes available. If interested, please click on "Sign Up" to register.

Purchase- Want immediate access to questions, answers, and teaching points? They can be purchased above at Apps and eBooks.


Sign Up
Bence Jones protein can be found in which of the following?



Click Your Answer Below


Would you like to access teaching points and more information on this topic?

Improve Content - Become an Author or Editor and get free access to the entire database, free eBooks, as well as free CME/CE as it becomes available. If interested, please click on "Sign Up" to register.

Purchase- Want immediate access to questions, answers, and teaching points? They can be purchased above at Apps and eBooks.


Sign Up
A 66-year-old male has multiple osteolytic punched-out lesions on plain radiography. What is the most likely diagnosis?



Click Your Answer Below


Would you like to access teaching points and more information on this topic?

Improve Content - Become an Author or Editor and get free access to the entire database, free eBooks, as well as free CME/CE as it becomes available. If interested, please click on "Sign Up" to register.

Purchase- Want immediate access to questions, answers, and teaching points? They can be purchased above at Apps and eBooks.


Sign Up
What is the MOST common presenting complaint of patients with multiple myeloma?



Click Your Answer Below


Would you like to access teaching points and more information on this topic?

Improve Content - Become an Author or Editor and get free access to the entire database, free eBooks, as well as free CME/CE as it becomes available. If interested, please click on "Sign Up" to register.

Purchase- Want immediate access to questions, answers, and teaching points? They can be purchased above at Apps and eBooks.


Sign Up
A 65-year-old male presents with vague pain and weight loss. Urine reveals proteinuria and skull radiographs show numerous radiolucent, "punched-out" lesions. These findings may be associated with which of the following?



Click Your Answer Below


Would you like to access teaching points and more information on this topic?

Improve Content - Become an Author or Editor and get free access to the entire database, free eBooks, as well as free CME/CE as it becomes available. If interested, please click on "Sign Up" to register.

Purchase- Want immediate access to questions, answers, and teaching points? They can be purchased above at Apps and eBooks.


Sign Up
What is the most significant cytogenetic abnormality in patients with multiple myeloma?



Click Your Answer Below


Would you like to access teaching points and more information on this topic?

Improve Content - Become an Author or Editor and get free access to the entire database, free eBooks, as well as free CME/CE as it becomes available. If interested, please click on "Sign Up" to register.

Purchase- Want immediate access to questions, answers, and teaching points? They can be purchased above at Apps and eBooks.


Sign Up
A 67-year-old male presents with multiple "punched out" skull lesions on a lateral radiograph associated with monoclonal gammopathy and amyloidosis. What is the most likely diagnosis?



Click Your Answer Below


Would you like to access teaching points and more information on this topic?

Improve Content - Become an Author or Editor and get free access to the entire database, free eBooks, as well as free CME/CE as it becomes available. If interested, please click on "Sign Up" to register.

Purchase- Want immediate access to questions, answers, and teaching points? They can be purchased above at Apps and eBooks.


Sign Up
A 65-year-old male presents with a 4 month history of general malaise and boney pain. X-rays show lytic lesions. Biopsy of a lesion on his spleen stains positive with Congo Red. The patient has a protein spike on electrophoresis. What is the patient's likely diagnosis?



Click Your Answer Below


Would you like to access teaching points and more information on this topic?

Improve Content - Become an Author or Editor and get free access to the entire database, free eBooks, as well as free CME/CE as it becomes available. If interested, please click on "Sign Up" to register.

Purchase- Want immediate access to questions, answers, and teaching points? They can be purchased above at Apps and eBooks.


Sign Up
A 61-year-old has multiple "punched out" skull lesions associated with monoclonal gammopathy and amyloidosis. What is the most likely diagnosis?



Click Your Answer Below


Would you like to access teaching points and more information on this topic?

Improve Content - Become an Author or Editor and get free access to the entire database, free eBooks, as well as free CME/CE as it becomes available. If interested, please click on "Sign Up" to register.

Purchase- Want immediate access to questions, answers, and teaching points? They can be purchased above at Apps and eBooks.


Sign Up
Which of the following is a common finding in a patient with multiple myeloma?



Click Your Answer Below


Would you like to access teaching points and more information on this topic?

Improve Content - Become an Author or Editor and get free access to the entire database, free eBooks, as well as free CME/CE as it becomes available. If interested, please click on "Sign Up" to register.

Purchase- Want immediate access to questions, answers, and teaching points? They can be purchased above at Apps and eBooks.


Sign Up
Which of the following is false about multiple myeloma?



Click Your Answer Below


Would you like to access teaching points and more information on this topic?

Improve Content - Become an Author or Editor and get free access to the entire database, free eBooks, as well as free CME/CE as it becomes available. If interested, please click on "Sign Up" to register.

Purchase- Want immediate access to questions, answers, and teaching points? They can be purchased above at Apps and eBooks.


Sign Up
Which of the following is NOT a neurologic manifestation of multiple myeloma?



Click Your Answer Below


Would you like to access teaching points and more information on this topic?

Improve Content - Become an Author or Editor and get free access to the entire database, free eBooks, as well as free CME/CE as it becomes available. If interested, please click on "Sign Up" to register.

Purchase- Want immediate access to questions, answers, and teaching points? They can be purchased above at Apps and eBooks.


Sign Up
A 67-year-old female is noted to have elevated protein and erythrocyte sedimentation rate on routine labs. White blood cell count is normal but platelets are decreased. Serum protein electrophoresis shows an M-protein spike. There are multiple lytic lesions on bone radiographs. Select the most probable diagnosis.



Click Your Answer Below


Would you like to access teaching points and more information on this topic?

Improve Content - Become an Author or Editor and get free access to the entire database, free eBooks, as well as free CME/CE as it becomes available. If interested, please click on "Sign Up" to register.

Purchase- Want immediate access to questions, answers, and teaching points? They can be purchased above at Apps and eBooks.


Sign Up
A 60-year-old male with no history presents with fatigue and bone pain in his hips, x-rays show lytic lesions of the pelvis, but bone scan is normal. What is the likely diagnosis?



Click Your Answer Below


Would you like to access teaching points and more information on this topic?

Improve Content - Become an Author or Editor and get free access to the entire database, free eBooks, as well as free CME/CE as it becomes available. If interested, please click on "Sign Up" to register.

Purchase- Want immediate access to questions, answers, and teaching points? They can be purchased above at Apps and eBooks.


Sign Up
A 72-year-old female complains of generalized weakness and low back pain progressing over the past four months. The back is minimally tender, but plain radiographs show osteoporosis and small lytic lesions in the ribs. Laboratories show a normochromic normocytic anemia and peripheral smear notes rouleaux formation. Urinalysis has proteinuria. Chemistry panel shows elevated alkaline phosphatase and calcium. Select the most likely diagnosis.



Click Your Answer Below


Would you like to access teaching points and more information on this topic?

Improve Content - Become an Author or Editor and get free access to the entire database, free eBooks, as well as free CME/CE as it becomes available. If interested, please click on "Sign Up" to register.

Purchase- Want immediate access to questions, answers, and teaching points? They can be purchased above at Apps and eBooks.


Sign Up
What is the most common cancer to affect bones?



Click Your Answer Below


Would you like to access teaching points and more information on this topic?

Improve Content - Become an Author or Editor and get free access to the entire database, free eBooks, as well as free CME/CE as it becomes available. If interested, please click on "Sign Up" to register.

Purchase- Want immediate access to questions, answers, and teaching points? They can be purchased above at Apps and eBooks.


Sign Up
What bone is most commonly affected in multiple myeloma?



Click Your Answer Below


Would you like to access teaching points and more information on this topic?

Improve Content - Become an Author or Editor and get free access to the entire database, free eBooks, as well as free CME/CE as it becomes available. If interested, please click on "Sign Up" to register.

Purchase- Want immediate access to questions, answers, and teaching points? They can be purchased above at Apps and eBooks.


Sign Up
What is Multiple myeloma associated with?



Click Your Answer Below


Would you like to access teaching points and more information on this topic?

Improve Content - Become an Author or Editor and get free access to the entire database, free eBooks, as well as free CME/CE as it becomes available. If interested, please click on "Sign Up" to register.

Purchase- Want immediate access to questions, answers, and teaching points? They can be purchased above at Apps and eBooks.


Sign Up
What condition is not present in multiple myeloma?



Click Your Answer Below


Would you like to access teaching points and more information on this topic?

Improve Content - Become an Author or Editor and get free access to the entire database, free eBooks, as well as free CME/CE as it becomes available. If interested, please click on "Sign Up" to register.

Purchase- Want immediate access to questions, answers, and teaching points? They can be purchased above at Apps and eBooks.


Sign Up
What is the definitive diagnostic test for multiple myeloma?



Click Your Answer Below


Would you like to access teaching points and more information on this topic?

Improve Content - Become an Author or Editor and get free access to the entire database, free eBooks, as well as free CME/CE as it becomes available. If interested, please click on "Sign Up" to register.

Purchase- Want immediate access to questions, answers, and teaching points? They can be purchased above at Apps and eBooks.


Sign Up
The multinucleated giant cells characteristic of myeloma kidney are derived from:



Click Your Answer Below


Would you like to access teaching points and more information on this topic?

Improve Content - Become an Author or Editor and get free access to the entire database, free eBooks, as well as free CME/CE as it becomes available. If interested, please click on "Sign Up" to register.

Purchase- Want immediate access to questions, answers, and teaching points? They can be purchased above at Apps and eBooks.


Sign Up
Myeloma kidney principally involves:



Click Your Answer Below


Would you like to access teaching points and more information on this topic?

Improve Content - Become an Author or Editor and get free access to the entire database, free eBooks, as well as free CME/CE as it becomes available. If interested, please click on "Sign Up" to register.

Purchase- Want immediate access to questions, answers, and teaching points? They can be purchased above at Apps and eBooks.


Sign Up
A 65-year-old woman presents with features of newfound back pain and abdominal pain. Complete blood work revealed pancytopenia, hypercalcemia, and renal failure. The patient underwent a bone marrow biopsy which revealed an 80% monoclonal plasma cell population. Serum protein electrophoresis revealed a serum M-protein of 5 grams. Which of the following treatment options is most appropriate in this setting?



Click Your Answer Below


Would you like to access teaching points and more information on this topic?

Improve Content - Become an Author or Editor and get free access to the entire database, free eBooks, as well as free CME/CE as it becomes available. If interested, please click on "Sign Up" to register.

Purchase- Want immediate access to questions, answers, and teaching points? They can be purchased above at Apps and eBooks.


Sign Up
A 67-year-old female patient with suspected multiple myeloma submits a urine sample for analysis. Urine dipstick is negative for protein. Should any further urine testing be performed and if so which test would be the most critical test to recommend?



Click Your Answer Below


Would you like to access teaching points and more information on this topic?

Improve Content - Become an Author or Editor and get free access to the entire database, free eBooks, as well as free CME/CE as it becomes available. If interested, please click on "Sign Up" to register.

Purchase- Want immediate access to questions, answers, and teaching points? They can be purchased above at Apps and eBooks.


Sign Up
Which of these statements regarding multiple myeloma is incorrect?



Click Your Answer Below


Would you like to access teaching points and more information on this topic?

Improve Content - Become an Author or Editor and get free access to the entire database, free eBooks, as well as free CME/CE as it becomes available. If interested, please click on "Sign Up" to register.

Purchase- Want immediate access to questions, answers, and teaching points? They can be purchased above at Apps and eBooks.


Sign Up
A 59-year-old man is evaluated for progressive fatigue of 3 months' duration and recent worsening of his chronic back pain. He also reports swelling of his lower extremities. He does not indicate problems with urination. Medical history is notable for chronic low back pain. His only medication is acetaminophen as needed. On physical examination, vital signs are normal. Deep palpation of the lower back elicits pain. He has 1+ edema of the lower extremities. Laboratory studies show hemoglobin 8.5 g/dL (85 g/L), leukocyte count 4000/microL (4 × 10^9/L), platelet count 300,000/microL (300 × 10^9/L), albumin 2.7 g/dL (27 g/L), calcium 13.4 mg/dL (3.4 mmol/L), creatinine 2.1 mg/dL (186 micromol/L), and total protein 9.2 g/dL (92 g/L). A radiograph of the lumbar spine shows a compression fracture of the L2 vertebral body. Which of the following is the most appropriate diagnostic test to perform next?



Click Your Answer Below


Would you like to access teaching points and more information on this topic?

Improve Content - Become an Author or Editor and get free access to the entire database, free eBooks, as well as free CME/CE as it becomes available. If interested, please click on "Sign Up" to register.

Purchase- Want immediate access to questions, answers, and teaching points? They can be purchased above at Apps and eBooks.


Sign Up

Cancer, Multiple Myeloma - References

References

Dhodapkar MV, MGUS to myeloma: a mysterious gammopathy of underexplored significance. Blood. 2016 Dec 8     [PubMed]
Mateos MV,Landgren O, MGUS and Smoldering Multiple Myeloma: Diagnosis and Epidemiology. Cancer treatment and research. 2016     [PubMed]
Röllig C,Knop S,Bornhäuser M, Multiple myeloma. Lancet (London, England). 2015 May 30     [PubMed]
Rajkumar SV, Updated Diagnostic Criteria and Staging System for Multiple Myeloma. American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting. 2016     [PubMed]
Mateos MV,San Miguel JF, Management of multiple myeloma in the newly diagnosed patient. Hematology. American Society of Hematology. Education Program. 2017 Dec 8     [PubMed]
Greipp PR,San Miguel J,Durie BG,Crowley JJ,Barlogie B,Bladé J,Boccadoro M,Child JA,Avet-Loiseau H,Kyle RA,Lahuerta JJ,Ludwig H,Morgan G,Powles R,Shimizu K,Shustik C,Sonneveld P,Tosi P,Turesson I,Westin J, International staging system for multiple myeloma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2005 May 20     [PubMed]
Palumbo A,Avet-Loiseau H,Oliva S,Lokhorst HM,Goldschmidt H,Rosinol L,Richardson P,Caltagirone S,Lahuerta JJ,Facon T,Bringhen S,Gay F,Attal M,Passera R,Spencer A,Offidani M,Kumar S,Musto P,Lonial S,Petrucci MT,Orlowski RZ,Zamagni E,Morgan G,Dimopoulos MA,Durie BG,Anderson KC,Sonneveld P,San Miguel J,Cavo M,Rajkumar SV,Moreau P, Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2015 Sep 10     [PubMed]
Durie BG, The role of anatomic and functional staging in myeloma: description of Durie/Salmon plus staging system. European journal of cancer (Oxford, England : 1990). 2006 Jul     [PubMed]
Smith D,Yong K, Advances in understanding prognosis in myeloma. British journal of haematology. 2016 Nov     [PubMed]
Terpos E,Kleber M,Engelhardt M,Zweegman S,Gay F,Kastritis E,van de Donk NW,Bruno B,Sezer O,Broijl A,Bringhen S,Beksac M,Larocca A,Hajek R,Musto P,Johnsen HE,Morabito F,Ludwig H,Cavo M,Einsele H,Sonneveld P,Dimopoulos MA,Palumbo A, European Myeloma Network guidelines for the management of multiple myeloma-related complications. Haematologica. 2015 Oct     [PubMed]

Disclaimer

The intent of StatPearls is to provide practice questions and explanations to assist you in identifying and resolving knowledge deficits. These questions and explanations are not intended to be a source of the knowledge base of all of medicine, nor is it intended to be a board or certification review of Nurse-Lab and Diagnostic Testing. The authors or editors do not warrant the information is complete or accurate. The reader is encouraged to verify each answer and explanation in several references. All drug indications and dosages should be verified before administration.

StatPearls offers the most comprehensive database of free multiple-choice questions with explanations and short review chapters ever developed. This system helps physicians, medical students, dentists, nurses, pharmacists, and allied health professionals identify education deficits and learn new concepts. StatPearls is not a board or certification review system for Nurse-Lab and Diagnostic Testing, it is a learning system that you can use to help improve your knowledge base of medicine for life-long learning. StatPearls will help you identify your weaknesses so that when you are ready to study for a board or certification exam in Nurse-Lab and Diagnostic Testing, you will already be prepared.

Our content is updated continuously through a multi-step peer review process that will help you be prepared and review for a thorough knowledge of Nurse-Lab and Diagnostic Testing. When it is time for the Nurse-Lab and Diagnostic Testing board and certification exam, you will already be ready. Besides online study quizzes, we also publish our peer-reviewed content in eBooks and mobile Apps. We also offer inexpensive CME/CE, so our content can be used to attain education credits while you study Nurse-Lab and Diagnostic Testing.